| Autor: |
Robert PH; EA CoBTeK/IA, University of Nice Sophia Antipolis Nice, France ; Centre Mémoire de Ressources et de Recherche, CHU de Nice Nice, France., König A; EA CoBTeK/IA, University of Nice Sophia Antipolis Nice, France ; Alzheimer Centrum Limburg, School of Mental health and Neurosciences, Maastricht University Maastricht, Netherlands., Amieva H; Centre INSERM U897-Epidemiology-Biostatistics, University of Bordeaux, ISPED Bordeaux, France., Andrieu S; Inserm, UMR1027 Toulouse, France ; Université de Toulouse III, UMR1027 Toulouse, France ; CHU de Toulouse, Service d'épidémiologie et Santé Publique Toulouse, France., Bremond F; EA CoBTeK/IA, University of Nice Sophia Antipolis Nice, France ; INRIA - STARS - Sophia Antipolis France., Bullock R; Kingshill Research Centre Swindon, UK., Ceccaldi M; Centre Mémoire de Ressources et de Recherche CHU de Marseille, France., Dubois B; CMRR CHU de Paris, IM2A, INSERM, UMR-S 975 (ICM) Paris, France ; Hôpital La Salpêtrière, Université Pierre et Marie Curie-Paris 6 Paris, France., Gauthier S; McGill Centre for Studies in Aging Verdun, QC, Canada., Kenigsberg PA; Fondation Médéric Alzheimer Paris, France., Nave S; pRED, Neuroscience, Roche, Centre Mémoire Basel, Switzerland., Orgogozo JM; Centre Mémoire de Ressources et de Recherche, CHU de Bordeaux Bordeaux, France., Piano J; Centre Mémoire de Ressources et de Recherche, CHU de Nice Nice, France., Benoit M; EA CoBTeK/IA, University of Nice Sophia Antipolis Nice, France., Touchon J; Centre Mémoire de Ressources et de Recherche, CHU de Montpellier Montpellier, France., Vellas B; INSERM UMR 1027, Gerontopole, CHU Toulouse Toulouse, France ; INSERM UMR1027, Université de Toulouse III Paul Sabatier Toulouse, France., Yesavage J; Palo Alto Veterans Affairs Health Care System Palo Alto, CA, USA ; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University Stanford, CA, USA., Manera V; EA CoBTeK/IA, University of Nice Sophia Antipolis Nice, France. |
| Abstrakt: |
Alzheimer's disease and other related disorders (ADRD) represent a major challenge for health care systems within the aging population. It is therefore important to develop better instruments to assess the disease severity and progression, as well as to improve its treatment, stimulation, and rehabilitation. This is the underlying idea for the development of Serious Games (SG). These are digital applications specially adapted for purposes other than entertaining; such as rehabilitation, training and education. Recently, there has been an increase of interest in the use of SG targeting patients with ADRD. However, this field is completely uncharted, and the clinical, ethical, economic and research impact of the employment of SG in these target populations has never been systematically addressed. The aim of this paper is to systematically analyze the Strengths, Weaknesses, Opportunities, and Threats (SWOT) of employing SG with patients with ADRD in order to provide practical recommendations for the development and use of SG in these populations. These analyses and recommendations were gathered, commented on and validated during a 2-round workshop in the context of the 2013 Clinical Trial of Alzheimer's Disease (CTAD) conference, and endorsed by stakeholders in the field. The results revealed that SG may offer very useful tools for professionals involved in the care of patients suffering from ADRD. However, more interdisciplinary work should be done in order to create SG specifically targeting these populations. Furthermore, in order to acquire more academic and professional credibility and acceptance, it will be necessary to invest more in research targeting efficacy and feasibility. Finally, the emerging ethical challenges should be considered a priority. |
